reference/15224182

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/15224182

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Comparative Study\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	63
issn	0098-7484
issueIdentifier	7
pageRange	853-63
publicationName	JAMA
startingPage	853
bibliographicCitation	Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003 Feb 19;289(7):853–63. doi: 10.1001/jama.289.7.853. PMID: 12588269.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8a48cdde95ee65d03ae6e5716d35d355 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c8d14b1d40a63bc53e5ed6cf437e8fbf http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8c7fdd499558e7421108910d9f92f1b4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0025c6e1a2520fe3770d8ad141bd3da1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b770a4c1fb7c58e9903e7d7fab808e7a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7249621b46d8f3f0eb7ad3fd3761a349 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_64ec36e485e2dcd2256f356ab190670e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d767d88bfd14168c14ed8944f20c88d2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_720a86f69c629aa8f7910fc707ac9741 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f3a9862513491ef51bfbe923afceaaa1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6a71086a94e91edab55f674cee3dac6f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9065acf6142f6799d5e9e9aa9fe31416 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e33a0812c617ccf075cc085316dc2bc6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c7c2ae46bb3add5b965a8a7212b05759 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_013947144e706410ab573637f5ba74b3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_aa0bdc0a911f934cc4fbd852d38e4ed1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_76b5b19aaedff712d6ce2c681efc56e8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c29bdb25ebb92e2de1f704bec4e7e8da http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bd8528aac0aae9fef017f63de2be227a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_627c1d2bad34f01314f967265b9c1863 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9d2a45bfea1aada1a104a4a201880a2e
date	2003-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/12588269 https://doi.org/10.1001/jama.289.7.853
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5346 https://portal.issn.org/resource/ISSN/0098-7484
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial
discusses	http://id.nlm.nih.gov/mesh/M0229697 http://id.nlm.nih.gov/mesh/M0016238 http://id.nlm.nih.gov/mesh/M0016224 http://id.nlm.nih.gov/mesh/M0465835 http://id.nlm.nih.gov/mesh/M0227707 http://id.nlm.nih.gov/mesh/M0017012 http://id.nlm.nih.gov/mesh/M0010187 http://id.nlm.nih.gov/mesh/M0011126 http://id.nlm.nih.gov/mesh/M0028424 http://id.nlm.nih.gov/mesh/M0018641 http://id.nlm.nih.gov/mesh/M0201405 http://id.nlm.nih.gov/mesh/M0008434 http://id.nlm.nih.gov/mesh/M0001357 http://id.nlm.nih.gov/mesh/M0001380
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D010975Q000627 http://id.nlm.nih.gov/mesh/D006629Q000031 http://id.nlm.nih.gov/mesh/D007431Q000517 http://id.nlm.nih.gov/mesh/D017225Q000009 http://id.nlm.nih.gov/mesh/D015906Q000009 http://id.nlm.nih.gov/mesh/D010446Q000627 http://id.nlm.nih.gov/mesh/D000925Q000627 http://id.nlm.nih.gov/mesh/D019039Q000037 http://id.nlm.nih.gov/mesh/D011994Q000627 http://id.nlm.nih.gov/mesh/D005343Q000627 http://id.nlm.nih.gov/mesh/D006493Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D007140Q000627 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D000077284 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D000911Q000627 http://id.nlm.nih.gov/mesh/D006470Q000517 http://id.nlm.nih.gov/mesh/D010455Q000627 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D015607Q000009 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D004359 http://id.nlm.nih.gov/mesh/D016019 http://id.nlm.nih.gov/mesh/D007511Q000517 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000077542 http://id.nlm.nih.gov/mesh/D005260
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2244 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_3.4.21.5 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_9b21d1a174c364b6f99c6662d34d6034 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8564 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID448812 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16129704 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8198 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12210218 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7969

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135830341 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135993536 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127563695

Total number of triples: 92.